Get Over It

Important Safety Information
Following parenteral use of phentolamine at doses between 5 and 15 times higher than the recommended dose of OraVerse (phentolamine mesylate), myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia, bradycardia, and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information for details.

The product information provided in this site is intended only for residents of the United States.